The stability and anti-mycobacterium activity of peptide derivative N22

Abstract

Abstract: Objective To study the stability and anti-microbial activity in vitro of a new polypeptide-peptide derivative N22. MethodsThe content change of the peptide derivative N22 and isoniazid(INH) in the neutral solution from 0 to 6 days at 37℃ was analyzed by HPLC. The anti-bacterial activity in vitro was detected by the 2-fold dilution assay and the AlamarBlue assay. ResultsThe Results of HPLC showed that peptide derivative N22 was more unstable than INH in the media. In vitro experiments, the peptide derivative N22 can inhibit M. tuberculosis better than INH, its minimum inhibitory concentration(MIC) was 50μg/ml. It had also the effect against E.coli, and the MIC for E.coli was 130μg/ml. ConclusionsThe peptide derivative N22 had better effect against M. tuberculosis and E.coli.

Key words: peptides, antitubercular agents, Mycobacterium tuberculosis

Gu Hao, Xu Jiajia, Wang Heyao. The stability and anti-mycobacterium activity of peptide derivative N22[J]. Chinese Journal of Antituberculosis, 2009, 31(5): 287-290.

References

[1] Cole ST,Brosch R,Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence [J]. Nature, 1998,393: 537.
[2] Blumberg HM,Burman WJ,Chaisson RE, Daley CL,Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American thoracic society/centers for disease control and prevention/infectious disease society of America: treatment of tuberculosis [J]. Am J Respir Cirt Care Med, 2003, 167(4): 603-662.
[3] 黄艳. 抗结核药物靶点的研究进展[J]. 中国处方药,2006, (12): 25-28.
[4] 刘伟,司书毅,肖春玲. 新型抗结核药物的研究进展[J]. 国外医药抗生素分册, 2006, 27（2）: 91-94.
[5] Andreu D, Carreo C, Linde C, Boman HG, Andersson M. Identification of an anti-mycobacterial domain in NK-lysin and granulysin [J]. J Bio Chem, 1999, 344: 845-849.
[6] Anderson DH, Sawaya MR, Cascio D, Ernst W, Modlin R, Krensky A, Eisenberg D. Granulysin crystal structure and a structure-derived lytic mechanism [J]. J Mol Biol, 2003, 325: 355-365.
[7] 张江清. 高效液相色谱法测定异烟肼片的含量[J]. 海峡药学, 2005, 17(1): 4-6.
[8] 丁振若. 现代检验医学[M]. 北京:人民军医出版社, 2007: 1210-1211.
[9] 谢惠安. 现代结核病学[M]. 北京:人民卫生出版社, 2000: 87-88.
[10] 陆宇,王彬,郑梅琴,赵伟杰,李芃. 应用Alamar Blue 和MT T 测定抗结核药物最低抑菌浓度的研究[J]. 中国防痨杂志, 2007, 29 (6 ): 499-501.
[11] Molina-Salinas GM, Pérez-López A, Becerril-Montes P, Salazar-Aranda R, Said-Fernández S, de Torres NW. Evaluation of the flora of Northern Mexico for in vitro antimicrobial and antituberculosis activity [J]. Journal of Ethnopharmacology, 2007, 109: 435-441.
[12] Epand RM, Epand RF. Modulation of membrane curvature by peptides [J]. Biopolymers, 2000, (55): 358-363.
[13] Schrder-Borm H, Willumeit R, Brandenburg K, Andr J. Molecular basis for membrane selectivity of NK-2,a potent peptide antibiotic derived from NK-lysin [J]. Biochimica et Biophysica Acta, 2003, (1612): 164- 171.

[1]	Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768.
[2]	YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806.
[3]	ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813.
[4]	ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820.
[5]	DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao. Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 826-831.
[6]	QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879.
[7]	SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717.
[8]	ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740.
[9]	ZHANG Jing, CHEN Xi, WANG Bin, FU Lei, LU Yu, CHEN Xiao-you. Establishment of modified propidium monoazide (PMAxx)-quantitative PCR assay and its application for identification of antituberculosis drug activity [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 472-480.
[10]	LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488.
[11]	ZHANG Xing,WANG Feng-ming,LYU Xu-feng,HUA Tian-qi,ZHANG Xue-jun,JIANG Jing-yi,DING Chen-li,ZHU Wei,XIA Guo-dong,JI Jun-min,ZHAO Fei. Analysis of influencing factors of Mycobacterium tuberculosis infection in HIV/AIDS patients [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 360-365.
[12]	ZHAO Jiao-jie,FU Lei,WANG Bin,ZHANG Lei,HU Ming-hao,LU Yu. Establishment and application of pharmacodynamics and pharmacokinetics model in vitro [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 372-379.
[13]	YANG Han,YANG Jing-fen,WU Hao,CUI Xiao-li,DANG Li-yun. Value of MicroDST test in detecting sensitivity of first-line anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 380-384.
[14]	GAO Tian-hui,SHU Wei,GAO Jing-tao,LU Yu,LI Qi. Analysis of clarithromycin resistance and its influencing factors in 254 patients with drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 259-265.
[15]	CHEN Yan-mei,HUANG Xin-chun,SUN Qi,ZHANG Chen-chen,WEN Wen-pei,CHEN Liang. Analysis of drug resistance in patients with smear-negative and culture-positive pulmonary tuberculosis in Guangdong province in 2016 [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 272-275.